<DOC>
	<DOC>NCT01875770</DOC>
	<brief_summary>This research is being done to assess the long term prognosis of patients treated with ranibizumab for edema due to retinal vein occlusion.</brief_summary>
	<brief_title>Continuing Assessment of Patients Treated With ranibizUmab for REtinal Vein Occlusion (CAPTURE)</brief_title>
	<detailed_description>People treated with ranibizumab for edema due to retinal vein occlusion as part of previous studies at the Wilmer Eye Institute and who are currently being seen by their ophthalmologist at the Wilmer Eye Institute are followed up to assess long term outcomes</detailed_description>
	<mesh_term>Retinal Vein Occlusion</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>All patients who have been enrolled in the following three trials will be included in the study: A) "A Pilot, OpenLabel Study of the Safety, Tolerability, and Bioactivity of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Vein Occlusions.", B) "Extended followup of patients with macular edema due to bRanch rETinal vein occlusion (BRVO) or centrAl retinal veIn occlusioN (CRVO) previously treated with intravitreal ranibizumab (RETAIN) " C) "RanibizumabDosE Comparison (0.5mg and 2.0mg) and the Role of LAser in the ManagemenT of REtinal Vein Occlusion A Pharmacodynamic Approach (RELATE)"</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Retinal Vein Occlusion</keyword>
</DOC>